Acetylcholinesterase (AChE) inhibitors show good therapeutic effects on myasthenia gravis, glaucoma, and Alzheimer's disease through reversible enzyme inhibition so as to increase the accumulation of acetylcholine in the synapse and then promote and prolong the function of acetylcholine. This evidence concerns the gene ACHE and myasthenia gravis.